FilingReader Intelligence
Changchun High-Tech subsidiary wins FDA approval for hypertension drug
July 29, 2025 at 05:18 PM UTC•By FilingReader AI
Changchun High & New Technology Industry Group announced its subsidiary Brillian Pharma received FDA approval for amlodipine besylate oral solution lyophilized powder (Sdamlo).
The hypertension drug targets patients aged six and above, including adults with swallowing difficulties, offering convenient administration and room-temperature storage.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000661•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Changchun High & New Technology Industry Group publishes news
Free account required • Unsubscribe anytime